Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMX 250

Next Previous
Search
Drug Profile

DMX 250

Alternative Names: Angiotensin receptor blocker/propagermanium; DMX-250; Propagermanium/angiotensin receptor blocker

Latest Information Update: 14 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dimerix Bioscience
  • Class Organometallic compounds; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Sep 2023 Discontinued - Preclinical for Non-alcoholic steatohepatitis in Australia (unspecified route) (Dimerix Bioscience pipeline, September 2023)
  • 28 Aug 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Australia
  • 05 Aug 2016 DMX 250 is available for licensing as of 05 Aug 2016. http://dimerix.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top